Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 15;18(3):391-403.
doi: 10.5009/gnl220346. Epub 2023 Aug 8.

Research Progress of Central and Peripheral Corticotropin-Releasing Hormone in Irritable Bowel Syndrome with Comorbid Dysthymic Disorders

Yi Feng Liang  1 , Xiao Qi Chen  1 , Meng Ting Zhang  2 , He Yong Tang  2 , Guo Ming Shen  2
Affiliations
Review

Research Progress of Central and Peripheral Corticotropin-Releasing Hormone in Irritable Bowel Syndrome with Comorbid Dysthymic Disorders

Yi Feng Liang et al. Gut Liver. .

Abstract

Irritable bowel syndrome (IBS) is considered a stress disorder characterized by psychological and gastrointestinal dysfunction. IBS patients not only suffer from intestinal symptoms such as abdominal pain, diarrhea, or constipation but also, experience dysthymic disorders such as anxiety and depression. Studies have found that corticotropin-releasing hormone plays a key role in IBS with comorbid dysthymic disorders. Next, we will summarize the effects of corticotropin-releasing hormone from the central nervous system and periphery on IBS with comorbid dysthymic disorders and relevant treatments based on published literatures in recent years.

Keywords: Corticotropin-releasing hormone; Dysthymic disorder; Irritable bowel syndrome; Review.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Effect of CRH on irritable bowel syndrome with comorbid dysthymic disorders. CNS, central nervous system; PVN, paraventricular nucleus; CRH, corticotropin-releasing hormone; CeA, central amygdala; CRHR1, corticotropin-releasing hormone receptor 1; LC, locus coeruleus; NE, norepinephrine; DRN, dorsal raphe nucleus; 5-HT, 5-hydroxytryptamine; MC, mast cell; IL-6, interleukin-6; EC, entero-chromaffin cell; PG, prostaglandin; EG, eosinophilic granulocyte.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Camilleri M. Management options for irritable bowel syndrome. Mayo Clin Proc. 2018;93:1858–1872. doi: 10.1016/j.mayocp.2018.04.032. - DOI - PMC - PubMed
    1. Radovanovic-Dinic B, Tesic-Rajkovic S, Grgov S, Petrovic G, Zivkovic V. Irritable bowel syndrome: from etiopathogenesis to therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018;162:1–9. doi: 10.5507/bp.2017.057.be52083f2591477cb1203a0c3069e92f - DOI - PubMed
    1. Li HY, Chen Y, Hu ZY, et al. Meta analysis of acupuncture and moxibustion for anxiety and depression in irritable bowel syndrome. Zhen Ci Yan Jiu. 2022;47:821–829. - PubMed
    1. Magdy R, Eid RA, Hassan M, et al. The potential impact of nutritional intake on symptoms severity in patients with comorbid migraine and irritable bowel syndrome. BMC Neurol. 2022;22:199. doi: 10.1186/s12883-022-02723-0.5dd304c15e374381bfa234c3c0ea8b6f - DOI - PMC - PubMed
    1. Ohlsson B. Extraintestinal manifestations in irritable bowel syndrome: a systematic review. Therap Adv Gastroenterol. 2022;15:17562848221114558. doi: 10.1177/17562848221114558.13d170fb7bef4a23ba0f2108fc77d2d5 - DOI - PMC - PubMed

LinkOut - more resources